CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro Abstract #1847

Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.
Aim(s): We investigated the effect of CXCR4 inhibition in preventing pNET spreading in vitro.
Materials and methods: Complement-dependent cytotoxicity (CDC), Ab-dependent cell cytotoxicity (ADCC), Ab-dependent cell phagocytosis (ADCP) and direct Ab-induced apoptosis were investigated in vitro using three pNET cell lines (BON1, CM, QGP1) treated with Ulo. Following their incubation with SDF-1, RNAseq was used to profile the transcriptome before and after treatment with the mAb. The effects of Ulo on pNET cell morphology, as well as migration and invasion towards liver and bone fragments were also studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives
Keywords: pNET, CXCR4, EMT, Ulocuplumab

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1520 Osteotropism of NETs: Role of the SDF1/CXCR4 Axis in Regulating EMT
Introduction: NETs metastasize to the bone in up to 20% of patients. The SDF1/CXCR4 axis is a key determinant of osteotropism, and we showed that NETs overexpressing CXCR4 are more likely to develop bone metastases.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Valeria Simone
Keywords: emt, cxcr4
#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)
Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Francesca Maria Rizzo
Keywords: CTC, CXCR4, bone
#908 Role of Epithelial-to-Mesenchymal Transition Markers in Predicting Bone and Visceral Metastases from NETs
Introduction: Epithelial-to-mesenchymal transition (EMT) of tumor cells has been recently postulated as a pivotal mechanism driving metastatic spread.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Valeria Simone
Keywords: EMT, biomarker
#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Dr. Mauro Cives
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist